GOLYMCA
Live / Applied — First extension granted (statement of use) (as of 12 Dec 2025)
What this means for you
Not registered yet, but its 05 Jul 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98634271
- Mark type
- Stylized text
- Filed
- 05 Jul 2024
- Published for opposition
- 13 May 2025
- Attorney of record
- Marilyn. F. Kelly
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressant preparations, pharmaceutical antibodies for medical use, and immunotherapy preparations for the treatment of cancer; cytokine inhibitory drugs being pharmaceutical preparations for the treatment of cancer; anticoagulants; Pharmaceutical preparations for human use that modulate the immune system for the treatment of immune-system related diseases and disorders; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy for the treatment of cancer; Pharmaceutical and biological preparations for human use, namely, stem cells for medical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use; Pharmaceutical preparations for human use for the treatment of neuropsychiatric disorders; therapeutic radiopharmaceutical preparations for human use for the treatment of cancer and solid tumors; diagnostic radiopharmaceutical preparations for human use; diagnostic preparations for human use for medical purposes; radiopharmaceutical preparations for human use in the nature of imaging and detection agents for diagnosing and monitoring cancer; biological preparations for human use in the nature of radio-isotope markers for therapeutic or diagnostic use; Pharmaceutical preparations for human use for the treatment of cystic fibrosis.
Owner
- Celgene Corporation, Princeton, NJ, US
- Celgene Corporation, Princeton, NJ, US
Prosecution history
- 13 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 12 Dec 2025 — SOU EXTENSION 1 GRANTED
- 12 Dec 2025 — SOU EXTENSION 1 FILED
- 12 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 08 Jul 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 13 May 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 13 May 2025 — PUBLISHED FOR OPPOSITION
- 07 May 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 10 Apr 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 01 Apr 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 01 Apr 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 01 Apr 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 08 Jan 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 08 Jan 2025 — NON-FINAL ACTION E-MAILED
- 08 Jan 2025 — NON-FINAL ACTION WRITTEN